Naseem Amin
Voorzitter bij BELLEROPHON THERAPEUTICS, INC.
Vermogen: 17 512 $ op 31-05-2024
Profiel
Naseem Amin is currently the Chief Executive Officer & Director at Orphalan SA, Chairman at Bellerophon Therapeutics, Inc., and Independent Director at Avadel Pharmaceuticals Plc.
Previously, he served as Chairman at Open House London Ltd., Executive Chairman at Arix Bioscience Plc, Director-Medical Marketing & Portfolio Strategy at Baxter Healthcare Corp., Chief Scientific Officer at Smith & Nephew plc, Head-International Business Development at Genzyme Corp., Venture Partner at Advent Venture Partners LLP, and Senior Vice President-Business Development at Biogen Idec Ltd.
Dr. Amin holds an MBA from Kellogg School of Management and a doctorate from UCL Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 07-06-2023 | 291 865 ( 2.39% ) | 17 512 $ | 31-05-2024 |
Actieve functies van Naseem Amin
| Bedrijven | Functie | Begin |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Voorzitter | 26-05-2021 |
| AVADEL PHARMACEUTICALS PLC | Directeur/Bestuurslid | 17-05-2024 |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Algemeen Directeur | 01-01-2017 |
Eerdere bekende functies van Naseem Amin
| Bedrijven | Functie | Einde |
|---|---|---|
| ARIX BIOSCIENCE PLC | Voorzitter | 30-04-2021 |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 31-12-2019 |
| SMITH & NEPHEW PLC | Hoofd Techniek/Wetenschap/O&O | 01-01-2014 |
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Corporate Officer/Principal | 01-01-2009 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-01-2005 |
Opleiding van Naseem Amin
| Kellogg School of Management | Masters Business Admin |
| UCL Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| SMITH & NEPHEW PLC | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| AVADEL PHARMACEUTICALS PLC | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| Bedrijven in privébezit | 6 |
|---|---|
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Open House London Ltd.
 Open House London Ltd. RestaurantsConsumer Services Open House London Ltd. was founded in 2013 and operates restaurants. The non-profit company is based in London, UK. | Consumer Services |
Orphalan SA
Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Health Technology |
